Matches in Wikidata for { <http://www.wikidata.org/entity/Q91155909> ?p ?o ?g. }
Showing items 1 to 49 of
49
with 100 items per page.
- Q91155909 description "artículu científicu espublizáu en xunetu de 2018" @default.
- Q91155909 description "im Juli 2018 veröffentlichter wissenschaftlicher Artikel" @default.
- Q91155909 description "scientific article published on 19 July 2018" @default.
- Q91155909 description "wetenschappelijk artikel" @default.
- Q91155909 description "наукова стаття, опублікована в липні 2018" @default.
- Q91155909 name "Secukinumab provides rapid and persistent relief in pain and fatigue symptoms in patients with ankylosing spondylitis irrespective of baseline C-reactive protein levels or prior tumour necrosis factor inhibitor therapy: 2-year data from the MEASURE" @default.
- Q91155909 name "Secukinumab provides rapid and persistent relief in pain and fatigue symptoms in patients with ankylosing spondylitis irrespective of baseline C-reactive protein levels or prior tumour necrosis factor inhibitor therapy: 2-year data from the MEASURE" @default.
- Q91155909 type Item @default.
- Q91155909 label "Secukinumab provides rapid and persistent relief in pain and fatigue symptoms in patients with ankylosing spondylitis irrespective of baseline C-reactive protein levels or prior tumour necrosis factor inhibitor therapy: 2-year data from the MEASURE" @default.
- Q91155909 label "Secukinumab provides rapid and persistent relief in pain and fatigue symptoms in patients with ankylosing spondylitis irrespective of baseline C-reactive protein levels or prior tumour necrosis factor inhibitor therapy: 2-year data from the MEASURE" @default.
- Q91155909 prefLabel "Secukinumab provides rapid and persistent relief in pain and fatigue symptoms in patients with ankylosing spondylitis irrespective of baseline C-reactive protein levels or prior tumour necrosis factor inhibitor therapy: 2-year data from the MEASURE" @default.
- Q91155909 prefLabel "Secukinumab provides rapid and persistent relief in pain and fatigue symptoms in patients with ankylosing spondylitis irrespective of baseline C-reactive protein levels or prior tumour necrosis factor inhibitor therapy: 2-year data from the MEASURE" @default.
- Q91155909 P1433 Q91155909-31BB5724-7E26-4B97-8BE6-51A91D7C502D @default.
- Q91155909 P1476 Q91155909-B935E08A-BD8E-4ECA-AD3C-385062851923 @default.
- Q91155909 P2093 Q91155909-16C6CEB5-1E84-4090-A6FF-9FB1E65898ED @default.
- Q91155909 P2093 Q91155909-2EE52AEC-298D-45C4-A01A-0B19855F4448 @default.
- Q91155909 P2093 Q91155909-4B794005-E497-4CF2-9A56-B6D4D47109A3 @default.
- Q91155909 P2093 Q91155909-602E37D7-E83B-4B78-83C3-DAEA999A5353 @default.
- Q91155909 P2093 Q91155909-A605BC20-2AE6-4B24-9239-2C01D1968C0D @default.
- Q91155909 P2093 Q91155909-B3B85013-88ED-491E-BADE-E564D8803CD8 @default.
- Q91155909 P304 Q91155909-CFC45057-384F-4B0E-8D97-EFD7B4202C8B @default.
- Q91155909 P31 Q91155909-2198820A-AE5F-4EFA-BFC0-488DD6D75CB0 @default.
- Q91155909 P433 Q91155909-E3473FA6-2090-427F-B708-0E715B77619A @default.
- Q91155909 P478 Q91155909-502E5AD6-7EEC-4E33-B078-0670165258DB @default.
- Q91155909 P50 Q91155909-8B7E6780-4441-47C8-8F0B-D1D2B1A8EB26 @default.
- Q91155909 P50 Q91155909-E4E74314-0796-4479-995F-94D47F8250A8 @default.
- Q91155909 P50 Q91155909-FD399FE2-6AD6-40F2-9700-471F48765D85 @default.
- Q91155909 P577 Q91155909-41F358F7-56E6-4C2E-BFD5-9912CEBD232E @default.
- Q91155909 P698 Q91155909-86C5E17A-FD2D-4DF4-B2FF-6999797D646C @default.
- Q91155909 P921 Q91155909-7A07F1A8-59E7-40CB-8391-47A968F4F9FD @default.
- Q91155909 P698 30148436 @default.
- Q91155909 P1433 Q15759225 @default.
- Q91155909 P1476 "Secukinumab provides rapid and persistent relief in pain and fatigue symptoms in patients with ankylosing spondylitis irrespective of baseline C-reactive protein levels or prior tumour necrosis factor inhibitor therapy: 2-year data from the MEASURE 2 study" @default.
- Q91155909 P2093 "Atul Deodhar" @default.
- Q91155909 P2093 "Bintu Sherif" @default.
- Q91155909 P2093 "Kunal K Gandhi" @default.
- Q91155909 P2093 "MEASURE 2 study group" @default.
- Q91155909 P2093 "Philip G Conaghan" @default.
- Q91155909 P2093 "Steffen M Jugl" @default.
- Q91155909 P304 "260-269" @default.
- Q91155909 P31 Q13442814 @default.
- Q91155909 P433 "2" @default.
- Q91155909 P478 "37" @default.
- Q91155909 P50 Q65660760 @default.
- Q91155909 P50 Q88283567 @default.
- Q91155909 P50 Q92751391 @default.
- Q91155909 P577 "2018-07-19T00:00:00Z" @default.
- Q91155909 P698 "30148436" @default.
- Q91155909 P921 Q52849 @default.